What is Erste Group Bank’s Estimate for BSX FY2026 Earnings?

Boston Scientific Corporation (NYSE:BSX) – Erste Group Bank reduced their FY2026 earnings per share (EPS) estimates for Boston Scientific in a research note issued on Thursday, April 2nd. Erste Group Bank analyst H. Engel now expects that the medical equipment provider will earn $3.45 per share for the year, down from their previous estimate of $3.46. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the prior year, the business posted $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

BSX has been the subject of several other reports. Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Canaccord Genuity Group reduced their price objective on Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Morgan Stanley reduced their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. TD Cowen reduced their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Finally, BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.05.

Boston Scientific Trading Down 1.2%

Shares of NYSE BSX opened at $61.83 on Wednesday. Boston Scientific has a 12 month low of $60.90 and a 12 month high of $109.50. The company has a market cap of $91.89 billion, a price-to-earnings ratio of 31.87, a P/E/G ratio of 0.97 and a beta of 0.78. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $73.35 and a 200-day simple moving average of $88.76.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BSX. Vanguard Group Inc. grew its holdings in Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after buying an additional 1,115,337 shares during the last quarter. State Street Corp grew its holdings in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Rathbones Group PLC grew its holdings in Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after buying an additional 477,680 shares during the last quarter. Synergy Asset Management LLC grew its holdings in Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares during the last quarter. Finally, Gladstone Institutional Advisory LLC grew its holdings in Boston Scientific by 39.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after buying an additional 14,700 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.34% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an “Outperform” rating after the CHAMPION-AF readout met primary safety and efficacy endpoints, reinforcing the clinical momentum behind BSX’s electrophysiology franchise and supporting medium-term revenue prospects. Leerink Reiterates Outperform on Boston Scientific
• Positive Sentiment: Citigroup kept a “Buy” stance on BSX while trimming its price target from $94 to $87 — still implying substantial upside from current levels, indicating continued analyst conviction despite near-term concerns. Citigroup Lowers Price Target
• Positive Sentiment: Boston Scientific closed its acquisition of Valencia Technologies, a deal that positions BSX to better compete with Medtronic in an under‑penetrated market and could expand addressable market over time. Boston Scientific closes buyout of Valencia Technologies
• Neutral Sentiment: Market commentary is asking whether the large pullback (stock trading near the low end of its 12‑month range) creates a buying opportunity or signals valuation concerns — useful background but not a single catalyst. Is It Time To Revisit Boston Scientific After This Year’s Sharp Share Price Pullback
• Neutral Sentiment: News pieces noting the stock “sank” in recent trading sessions reflect market reaction to the mix of positive news and widening headline/legal noise rather than a single fundamental update. Boston Scientific Stock Sinks As Market Gains
• Negative Sentiment: Multiple law firms (Rosen, Pomerantz, Bernstein Liebhard, Gross, Faruqi, Levi & Korsinsky, Glancy, etc.) have issued investor alerts and a securities class action has been filed alleging concealment of demand weakness in electrophysiology — this legal scrutiny raises potential litigation costs, distraction and near‑term headline risk. Rosen Law Firm Investor Alert Pomerantz Investor Alert
• Negative Sentiment: Kahn Swick & Foti announced an investigation into the Penumbra sale process (Penumbra shareholders to receive cash or BSX stock), which could complicate or delay integration/planned terms and create additional transaction risk for BSX. Penumbra investor alert

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.